Cabot Drops 5% After Earnings as Options Hit 52-Week Extreme

CBT has just reported its fiscal fourth-quarter results, and the market's immediate reaction confirms what the most extreme options positioning in a year was signalling: a sharp repricing downward.

The options market told the starkest story heading into the print. The put/call ratio hit 1.54 on November 3, the highest reading of the past 52 weeks and 3.6 standard deviations above its 20-day mean of 0.24. That is not normal hedging activity. For most of October, the PCR ran below 0.13. The jump to 1.54 represented a surge in demand for downside protection that was dramatically out of character for the stock, and it proved well-placed: CBT fell roughly 3.3% on the day of the print and a further 4.9% on November 3, leaving the stock at $72.00 and down 6.4% over the past month.

Short interest had already been building ahead of this point, as noted in the earnings preview published November 3. That pre-results short position, which reached 9.4% of the free float, has edged back very slightly to 9.3% now, but the broader picture is unchanged: CBT remains the most actively shorted name among its closest specialty chemicals peers. The month-on-month increase is still 9.2%, meaning the bulk of the short buildup happened before the print, not after it. The borrow market remains unconstrained. Availability is running at 601%, up from 575% a week ago, meaning roughly six shares are available to borrow for every one already lent out. That is well above the 52-week floor of 362%. Cost to borrow is negligible at 0.56%. There is no squeeze pressure, and plenty of room for shorts to maintain or extend positions without facing a supply constraint.

The Street's response to the results has been swift. Truist Securities lowered its target from $100 to $95 on November 4, while keeping a Buy rating. That action is worth noting: the firm only initiated coverage in June with a $98 target. Within five months, the target has come down $3. Looking at the broader analyst picture, the mean price target remains $89.50, implying around 24% upside from current levels at $72. But the direction of travel in targets is downward: UBS has trimmed twice this year, most recently to $86, while maintaining Neutral. JP Morgan carries an Underweight with a $78 target. On valuation, the stock trades at roughly 9.7x trailing earnings and 6.0x EV/EBITDA, both of which have compressed over the past 30 days alongside the price. The earnings yield factor scores in the 83rd percentile, so on a pure cheapness basis, the stock is not expensive. The short score rank of 4 and days-to-cover rank of 3 reflect that short positioning remains heavy in a cross-sectional context.

One flow worth flagging is in the institutional register. American Century added 530,685 shares in Q3, one of the larger active additions among the top holders. T. Rowe Price added 767,198 shares over the same period, bringing its stake to 4.3% of shares outstanding. Those are meaningful additions from active managers buying into a period when the stock was trading considerably higher. Wellington Management, by contrast, trimmed its stake from 7.8% to 4.7% between May 2025 and August 2026, a gradual reduction that represents the other side of the institutional debate. CEO Sean Keohane exercised and sold options across multiple transactions in August, netting roughly $19.6 million on a 90-day basis. The sales were not under a 10b5-1 plan, though the exercise-and-sell structure is a common compensation mechanism rather than a discretionary bearish call.

Wikipedia attention data from the ORTEX Alt Data layer is worth noting as colour. Retail attention spiked to a z-score of 2.35 in the week of October 22, running well above the prior 90-day average. That attention spike preceded a week in which options positioning turned dramatically defensive and the stock fell sharply. There is no measured lead for CBT's Wikipedia traffic against its reported figures, so no causal link can be drawn, but the timing illustrates how unusual retail interest can coincide with vol events.

The next earnings date is February 1, 2027, leaving 89 days for the market to reprice the thesis. With shorts still near a year-high, options at a 52-week extreme reading that has now partially resolved, and analysts trimming targets while mostly holding positive ratings, the question for the coming weeks is whether the post-results selling pressure draws in further short interest or whether the valuation compression at roughly 9.7x earnings begins to attract the active buyers who were adding in Q3.